Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy

Samantha Haraszti; Samantha Polly; Harib H Ezaldein; Robert Rothbaum; Gregory R Delost; Mara Beveridge

doi:10.1016/j.jdcr.2019.03.014

Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy

JAAD Case Rep. 2019 Jun 8;5(6):514-517. doi: 10.1016/j.jdcr.2019.03.014. eCollection 2019 Jun.

Authors

Samantha Haraszti¹, Samantha Polly², Harib H Ezaldein², Robert Rothbaum², Gregory R Delost², Mara Beveridge²

Affiliations

¹ Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
² Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

No abstract available

Keywords: Dynavax; PD-1, programmed cell death protein 1; SCC, squamous cell carcinoma; SD-101; TLR9 agonist; TLRs, toll-like receptors; cSCC, cutaneous squamous cell carcinoma; checkpoint inhibitor therapy; eruptive squamous cell carcinomas; immune-related adverse events; matrix-metalloproteinase 13; metastatic melanoma; pembrolizumab.

Publication types

Case Reports